FGFR2 and neoplasm: Droplet Digital PCR technology validated the ARID1A mutation (Figure 4A and Supplementary Figure 3A) and the FGFR2 amplification (Figure 4B and Supplementary Figure 3B) in bulk tumor DNA and in longitudinally collected ccfDNAs at three different time points of disease evolution.